MOG antibody testing in ADS children evaluated

Lesen Sie diesen Artikel auf Deutsch.

Testing children for anti-MOG (myelin oligodendrocyte glycoprotein) antibodies at the time of clinical onset of acquired demyelinating syndromes (ADS) could help identify a subgroup with distinct clinical and MRI features, new research suggests.

Presenting at ECTRIMS 2018, Dr Giulia Fadda of McGill University, Montreal, Canada, reported data from a study in which anti-MOG antibody status was assessed in children with incident ADS, recruited for the Canadian Demyelinating Disease Study.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.